Recent case law impacting the definitions of prior sales will drive changes in vendor relationships and contracting. In particular, virtual or asset-light emerging growth companies that use vendors for synthesizing, analyzing, or conducting clinical trials may need to adjust their contracting behavior going forward to preserve necessary intellectual property rights.

What your competitors don’t know can hurt you: Strategies to avoid secret sales from invalidating your patent

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.